REG - MyHealthChecked PLC - Result of General Meeting

MyhealthcheckedAnnouncement

18/02/2021 11:25

RNS Number : 5954P
  
MyHealthChecked PLC
  
18 February 2021
  
 

 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
 
 
MyHealthChecked plc
("MyHealthChecked" or "the Company")
 
Result of General Meeting
 
At the General Meeting held earlier today both the resolutions were duly approved by shareholders:
 




Resolution (*indicates special resolution)


Votes for (1)


% of shares voted (2)


Votes against (3)


% of shares voted




Resolution 1: to authorise the Directors to allot shares in the Company
 


112,032,017


98.55%


1,644,084


1.45%




Resolution 2*: to disapply pre-emption rights
 


110,130,337


97.73%


2,562,865


2.27%




 
Notes:
 
(1)  Any proxy appointments which gave discretion to the Chairman have been included in the "for" total.
(2)  As a percentage of the aggregate of votes "for" plus votes "against".
(3)  An abstention is not counted towards the votes cast "for" or "against" a resolution.
 
Allotment of Shares
 
At a board meeting following the General Meeting, the Company has allotted 207,424,361 new ordinary shares of 0.1p each ("Ordinary Shares") comprising 126,628,576 Placing Shares, 39,085,710 Firm Subscription Shares, 28,571,428 Conditional Placing Shares and 13,138,647 Conversion Shares. 
 
Application has been made for the admission to trading on AIM ("First Admission") of the Placing Shares, the Firm Subscription Shares and the Conversion Shares (amounting to 178,852,933 new Ordinary Shares), and First Admission is expected at 8.00 a.m. on or around 19 February 2021.
 
Application has been made for the admission to trading on AIM ("Second Admission") of the Conditional Subscription Shares (amounting to 28,571,428 new Ordinary Shares), and Second Admission is expected at 8.00 a.m. on or around 22 February 2021.
 
Total Voting Rights
 
Following First Admission, the Company's issued share capital will comprise 696,674,608 ordinary shares with one voting right each. As the Company does not hold any shares in Treasury, the total number of voting rights in the Company is also 696,674,608 and this figure of ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
Following Second Admission, the Company's issued share capital will comprise 725,246,036 ordinary shares with one voting right each, and total number of voting rights in the Company will be 725,246,036.
 
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 29 January 2021 unless the context requires otherwise.
 
For further information please visit http://www.myhealthcheckedplc.com/ or contact:
 




MyHealthChecked plc


www.myhealthcheckedplc.com




Penny McCormick, Chief Executive Officer


via Walbrook PR




Maddy Kennedy, Chief Financial Officer


 




 


 




SPARK Advisory Partners Limited (NOMAD)


Tel: +44 (0)20 3368 3550




Neil Baldwin


 




 


 




Oberon Investments (Broker)


Tel: +44 (0)203 179 5344




Mike Seabrook


mikeseabrook@oberoninvestments.com




 


 




Walbrook PR Ltd (Media & Investor Relations)


Tel: +44 (0)20 7933 8780 or myhealthchecked@walbrookpr.com




Paul McManus


Mob: +44(0)7980 541 893




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ROMFVLFFFLLFBBV